Similarly, the glucagon-like peptide-1 receptor (GLP-1R) is well established as a therapeutic target for type 2 diabetes and obesity, with GLP-1R agonists effectively lowering glucose levels and promoting weight loss. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.